Fenbendazole and Bladder Cancer

Fenbendazole and Bladder Cancer — A Scientific Overview. In recent years, fenbendazole (often shortened to “fenben”) has gained attention online as a possible alternative cancer therapy. Stories circulating on social media claim dramatic responses in various cancers, including bladder cancer.

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths beyond conventional, FDA-approved therapies and taken great risks in an effort to manage my blood cancer.  I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.

The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and bladder cancer debate. Please scroll down the page, post a question or a comment if you have any questions.

Thank you,

David Emerson

• Cancer Survivor
• Cancer Coach
• Director PeopleBeatingCancer

What Is Fenbendazole?

Fenbendazole (also called fenben or FBZ) is a benzimidazole antiparasitic drug most often used in veterinary medicine to treat worms in animals such as dogs, cats, horses, sheep, goats, and livestock. It works by binding to tubulin in parasitic cells, disrupting microtubule formation, and thereby interfering with parasite energy metabolism and growth.

Although drugs that target microtubules (such as vincristine and paclitaxel) are used in cancer treatment, fenbendazole itself is not approved by the FDA for any human use, including cancer therapy.

Why People Talk About Fenbendazole for Cancer

Over the past decade, health blogs and social media have circulated stories claiming dramatic cancer responses after people took fenbendazole. These claims have sparked interest in repurposing this inexpensive drug as an anticancer agent. Some case reports and patient anecdotes claim tumor shrinkage or remission, but they are anecdotal and not controlled clinical evidence.

How Fenbendazole Could Treat Cancer (and Why It Won’t)

What Research Really Shows

Laboratory and Preclinical Studies

Laboratory studies have shown that fenbendazole can:

• Bind to tubulin and disrupts microtubules, a mechanism that is similar to some chemotherapy drugs.
• Inhibit energy metabolism and induce cell death in some cancer cell lines grown in a dish.

However, preclinical work on fenbendazole’s effect in live animal models has mixed or negative results:

• In lymphoma models, fenbendazole did not slow tumor growth when given to mice, despite in vitro toxicity toward lymphoma cell lines.
• Some older animal studies that saw reduced tumor burden combined fenbendazole with other agents (like vitamins), making it difficult to isolate fenbendazole’s effect.

No well-designed clinical trials have shown that fenbendazole treats cancer in humans.

Bladder Cancer and Fenbendazole — What We Know

Research specifically exploring fenbendazole and bladder cancer is currently very limited. However, some recent studies in cancer biology suggest:

• Fenbendazole influences pathways such as ferroptosis, autophagy, and cell cycle arrest, which are being studied in a number of cancer models.
• One preclinical review suggests that fenbendazole may have antitumor activity across various cancers, including genitourinary malignancies (a category that includes bladder cancer), but the evidence is insufficient to draw conclusions.

This does not mean fenbendazole is proven effective for bladder cancer. It means some lab studies are investigating mechanisms, not that we have any clinical proof it works in people.

Limitations of Current Evidence

• No human clinical trials: Fenbendazole has not been tested in rigorous clinical studies for bladder cancer or other solid tumors.
• Animal research doesn’t always translate: What works in cell lines or mice often fails in human subjects.
• Bioavailability issues: Oral fenbendazole has poor absorption in humans, and how to deliver it effectively to tumors is unresolved.

Safety and Risks

Fenbendazole is not formulated for human use, and long-term safety at doses that might be needed to affect tumors in humans is unknown. Some off-label use reports describe liver toxicity and interactions with other medications.

Bottom Line: What Patients Should Know

• There is no high-quality clinical evidence that fenbendazole treats bladder cancer or any other cancer in humans.
• Laboratory and early animal studies suggest potential mechanisms, but promise in the lab does not mean effectiveness in people.
• Using unproven treatments without medical supervision can delay proven therapies and pose safety risks.

If you or a loved one is considering experimental or off-label therapies like fenbendazole, it’s essential to discuss them with your oncologist or medical team.

Citations

• https://link.springer.com/article/10.1186/s13046-024-03146-0?utm_source=chatgpt.com
• https://www.cancer.org/cancer/latest-news/what-to-know-about-fenbendazole.html?utm_source=chatgpt.com
• https://www.anticancerfund.org/en/blog/separating-fact-fiction-repurposed-drugs-cancer-treatment?utm_source=chatgpt.com

Fenbendazole and Bladder Cancer Fenbendazole and Bladder Cancer Fenbendazole and Bladder Cancer